Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs

Annals of the New York Academy of Sciences

Volumn 1187, Issue , 2010, Pages 218-246

  Sora, Ichiro ^a   Li, Bingjin ^a   Igari, Moe ^a   Hall, F Scott ^b   Ikeda, Kazutaka ^c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Amphetamine; Cocaine; Knockout; Psychostimulant; Transgenic

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; AMPHETAMINE; COCAINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; METHYLPHENIDATE; NORADRENALIN; NORADRENALIN TRANSPORTER; PSYCHOSTIMULANT AGENT; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2;

BEHAVIOR; DISEASE MODEL; DRUG DEPENDENCE; DRUG EFFECT; GENE EXPRESSION; KNOCKOUT MOUSE; NONHUMAN; PHENOTYPE; PREPULSE INHIBITION; REVIEW; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

EID: 77949301555     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05276.x     Document Type: Review

References (188)

1. Sora, I. et al. 1997. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. USA 94: 1544-1549.
2. Takahashi, N. et al. 1997. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. USA 94: 9938-9943.
3. Sora, I. et al. 1998.Cocaine rewardmodels: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. Sci. USA 95: 7699-7704.
4. Crabbe, J.C. et al. 1999. Identifying genes for alcohol and drug sensitivity: recent progress and future directions. Trends Neurosci. 22: 173-179.
5. Uhl, G.R., F.S. Hall & I. Sora. 2002. Cocaine, reward, movement and monoamine transporters. Mol. Psychiatry 7: 21-26.
6. Uhl, G.R. et al. 2000. The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J. 14: 2459-2465.
7. Kuhar, M.J.,M.C.Ritz&J.W. Boja. 1991. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 14: 299-302.
8. Van Den Bree, M.B. et al. 1998. Genetic and environmental influences on drug use and abuse/dependence in male and female twins. Drug Alcohol Depend. 52: 231-241.
9. Ujike, H. et al. 2003. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J. 3: 242-247.
10. Rocha, B.A. et al. 1998. Cocaine self-administration in dopamine-transporter knockout mice. Nat. Neurosci. 1: 132-137.
11. Medvedev, I.O. et al. 2005. Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice. Psychopharmacology (Berl) 180: 408-413.
12. Morice, E. et al. 2004. Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background. Eur. J. Neurosci. 20: 120-126.
13. Homberg, J.R. et al. 2008. Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats. Psychopharmacology (Berl) 200: 367-380.
14. Harrison, A.A. et al. 1999. RU 24969, a 5-HT1A/1B agonist, elevates brain stimulation reward thresholds: an effect reversed by GR 127935, a 5-HT1B/1D antagonist. Psychopharmacology (Berl) 141: 242-250.
15. Rocha, B.A. et al. 1998. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature 393: 175-178.
16. Sora, I. et al. 2001. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl. Acad. Sci. USA 98: 5300-5305.
17. Xu, F. et al. 2000. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants.Nat. Neurosci. 3: 465-471.
18. Hall, F.S. et al. 2002. Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience 115: 153-161.
19. Thomsen, M. et al. 2009. Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. J. Neurosci. 29: 1087-1092.
20. Shen, H.W. et al. 2004. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29: 1790-1799.
21. Carboni, E. et al. 2001. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J. Neurosci. 21: 1-4.
22. Hummel, M. et al. 2004. Genetic and pharmacological manipulation of mu opioid receptors in mice reveals a differential effect on behavioral sensitization to cocaine. Neuroscience 125: 211-220.
23. Donovan, D.M. et al. 1999. Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Brain Res. Mol. Brain Res. 73: 37-49.
24. Gainetdinov, R.R. & M.G. Caron. 2003. Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol. 43: 261-284.
25. Zhuang, X. et al. 2001. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl. Acad. Sci. USA 98: 1982-1987.
26. Tilley,M.R. et al. 2007.Cocaine reward and locomotion stimulation in micewith reduced dopamine transporter expression. BMC Neurosci. 8: 42.
27. Wang, Y.M. et al. 1997. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19: 1285-1296.
28. Yamamoto, H. et al. 2007. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture. Neurochem. Int. 51: 237-244.
29. Seeman, P., F.S. Hall & G. Uhl. 2007. Increased dopamine D2High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse 61: 573-576.
30. Seeman, P. 2009. Dopamine D2High receptors measured ex vivo are elevated in amphetamine-sensitized animals. Synapse 63: 186-192.
31. Chen, R. et al. 2006. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc. Natl. Acad. Sci. USA 103: 9333-9338.
32. Tilley, M.R. et al. 2009. Cocaine does not produce reward in absence of dopamine transporter inhibition. Neuroreport 20: 9-12.
33. Thomsen, M. et al. 2009. Lack of cocaine selfadministration in mice expressing a cocaine-insensitive dopamine transporter. J. Pharmacol. Exp. Ther. 331: 204-211.
34. Tilley, M.R. & H.H. Gu. 2008. Dopamine transporter inhibition is required for cocaine-induced stereotypy. Neuroreport 19: 1137-1140.
35. Murphy,D.L. et al. 2003. Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. Genes Brain Behav. 2: 350-364.
36. Mateo, Y. et al. 2004. Role of serotonin in cocaine effects in mice with reduced dopamine transporter function. Proc. Natl. Acad. Sci. USA 101: 372-377.
37. Hnasko, T.S., B.N. Sotak & R.D. Palmiter. 2007. Cocaine-conditioned place preference by dopaminedeficient mice ismediated by serotonin. J. Neurosci. 27: 12484-12488.
38. Robinson, S. et al. 2004. Firing properties of dopamine neurons in freely moving dopamine-deficient mice: effects of dopamine receptor activation and anesthesia. Proc. Natl. Acad. Sci. USA 101: 13329-13334.
39. Robinson,T.E.&J.B. Becker. 1986. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animalmodels of amphetamine psychosis. Brain Res. 396: 157-198.
40. Kalivas, P.W., B.A. Sorg & M.S. Hooks. 1993. The pharmacology and neural circuitry of sensitization to psychostimulants. Behav. Pharmacol. 4: 315-334.
41. Kalivas, P.W. & J. Stewart. 1991. Dopamine transmission in the initiation and expression of drug- and stressinduced sensitization of motor activity. Brain Res. Brain Res. Rev. 16: 223-244.
42. Giros, B. et al. 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612.
43. Gainetdinov, R.R. et al. 1999. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283: 397-401.
44. Mead, A.N. et al. 2002. Intravenous cocaine induced-activity and behavioural sensitization in norepinephrine-, but not dopamine-transporter knockout mice. Eur. J. Neurosci. 16: 514-520.
45. Drgon, T. et al. 2006. Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol. Neurobiol. 26: 875-889.
46. Hall, F.S. et al. 2009. Cocaine-conditioned locomotion in dopamine transporter, norepinephrine transporter and 5-HT transporter knockout mice. Neuroscience. 16: 870-880.
47. Gainetdinov, R.R. 2008. Dopamine transporter mutant mice inexperimentalneuropharmacology.Naunyn Schmiedebergs Arch. Pharmacol. 377: 301-313.
48. Gainetdinov, R.R. & M.G. Caron. 2001. Genetics of childhood disorders: XXIV. ADHD, part 8: hyperdopaminergic mice as an animal model of ADHD. J. Am. Acad. Child Adolesc. Psychiatry 40: 380-382.
49. Barr, A.M. et al. 2004. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology 29: 221-228.
50. Ralph, R.J. et al. 2001. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J. Neurosci. 21: 305-313.
51. Yamashita, M. et al. 2006. Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 31: 2132-2139.
52. Carboni, E. et al. 1990. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 55: 1067-1070.
53. Moron, J.A. et al. 2002. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J. Neurosci. 22: 389-395.
54. Isner, J.M. et al. 1986. Acute cardiac events temporally related to cocaine abuse. N. Engl. J. Med. 315: 1438-1443.
55. Olson, K.R. et al. 1993. Seizures associated with poisoning and drug overdose.Am. J. Emerg. Med. 11: 565-568.
56. Kaminski, R.M. et al. 2005. Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures. Neurosci. Lett. 382: 51-55.
57. Han, D.D. & H.H. Gu. 2006. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.BMCPharmacol. 6: 6.
58. Rothman, R.B. & M.H. Baumann. 2003. Monoamine transporters and psychostimulant drugs. Eur. J. Pharmacol. 479: 23-40.
59. Seiden, L.S., K.E. Sabol & G.A. Ricaurte. 1993. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33: 639-677.
60. Sulzer, D. et al. 2005. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75: 406-433.
61. Fon, E.A. et al. 1997. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19: 1271-1283.
62. Mooslehner,K.A. et al. 2001.Micewith very lowexpression of the vesicularmonoamine transporter 2 gene survive into adulthood: potential mousemodel for parkinsonism. Mol. Cell. Biol. 21: 5321-5331.
63. Jones, S.R. et al. 1998. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. USA 95: 4029-4034.
64. Budygin, E.A. et al. 2004. Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine. Proc. Natl. Acad. Sci. USA 101: 7781-7786.
65. Jones, S.R. et al. 1999. Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat. Neurosci. 2: 649-655.
66. Shi, W.X. et al. 2000. Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. J. Neurosci. 20: 3504-3511.
67. Spielewoy, C. et al. 2001. Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter. Psychopharmacology (Berl) 159: 2-9.
68. Beaulieu, J.M. et al. 2006. Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J. Biol. Chem. 281: 32072-32080.
69. Salahpour, A. et al. 2008. Increased amphetamineinduced hyperactivity and reward in mice overexpressing the dopamine transporter.Proc.Natl.Acad. Sci.USA 105: 4405-4410.
70. Fukushima, S. et al. 2007. Methamphetamine-induced locomotor activity and sensitization indopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology (Berl) 193: 55-62.
71. Bengel, D. et al. 1998. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4- methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol. Pharmacol. 53: 649-655.
72. Davidson,C. et al. 2001.Methamphetamine neurotoxicity: necrotic and apoptoticmechanisms and relevance to human abuse and treatment. Brain Res. Brain Res. Rev. 36: 1-22.
73. Broening,H.W., L.L.Morford&C.V.Vorhees. 2005. Interactions of dopamineD1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse 56: 84-93.
74. Bronstein, D.M. & J.S. Hong. 1995. Effects of sulpiride and SCH 23390 on methamphetamineinduced changes in body temperature and lethality. J. Pharmacol. Exp. Ther. 274: 943-950.
75. Green, A.R. et al. 2003. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55: 463-508.
76. Numachi, Y. et al. 2007. Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur. J. Pharmacol. 572: 120-128.
77. Wagner, G.C. et al. 1980. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181: 151-160.
78. Ricaurte,G.A., C.R. Schuster&L.S. Seiden. 1980. Longterm effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 193: 153-163.
79. Fumagalli, F. et al. 1998. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence frommice lacking the transporter. J.Neurosci. 18: 4861-4869.
80. Fumagalli, F. et al. 1999. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19: 2424-2431.
81. Guillot, T.S. et al. 2008. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. J. Neurochem. 106: 2205-2217.
82. Gainetdinov, R.R. et al. 1998. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70: 1973-1978.
83. Kariya, S. et al. 2005. Increased vulnerability to L-DOPA toxicity in dopaminergic neurons from VMAT2 heterozygote knockout mice. J. Mol. Neurosci. 27: 277-279.
84. Reveron, M.E. et al. 2002. L-DOPA does not cause neurotoxicity inVMAT2 heterozygote knockout mice. Neurotoxicology 23: 611-619.
85. Liu, Y. et al. 1992. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70: 539-551.
86. Larsen, K.E. et al. 2002. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22: 8951-8960.
87. Rothman, R.B. & M.H. Baumann. 2002. Serotonin releasing agents.Neurochemical, therapeutic and adverse effects. Pharmacol. Biochem. Behav. 71: 825-836.
88. Cami, J. et al. 2000. Human pharmacology of 3,4- methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J. Clin. Psychopharmacol. 20: 455-466.
89. Rothman, R.B. et al. 2001. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
90. Bilsky, E.J. et al. 1998. CGS 10746B, a novel dopamine release inhibitor, blocks the establishment of cocaine andMDMA conditioned place preferences. Pharmacol. Biochem. Behav. 59: 215-220.
91. Daniela, E. et al. 2004. Effect of SCH 23390 on (+/?)-3,4- methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol. Biochem. Behav. 77: 745-750.
92. Schmidt, C.J., J.A. Levin & W. Lovenberg. 1987. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem. Pharmacol. 36: 747-755.
93. Trigo, J.M. et al. 2007. 3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol. Psychiatry 62: 669-679.
94. Fabre,V. et al. 2000.Homeostatic regulation of serotonergic function by the serotonin transporter as revealed by nonviral gene transfer. J. Neurosci. 20: 5065-5075.
95. Mathews, T.A. et al. 2004. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J. Neurosci. Methods 140: 169-181.
96. Renoir, T. et al. 2008. Differential long-term effects of MDMA on the serotoninergic system and hippocampal cell proliferation in 5-HTT knock-out vs. wildtype mice. Int. J. Neuropsychopharmacol. 11: 1149-1162.
97. Baumann, M.H., X. Wang & R.B. Rothman. 2007. 3,4- Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189: 407-424.
98. Fornai, F. et al. 2001. Biochemical effects of the monoamine neurotoxins DSP-4 and MDMA in specific brain regions of MAO-B-deficient mice. Synapse 39: 213-221.
99. Gatley, S.J. et al. 1996. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci. 58: 231-239.
100. Trinh, J.V. et al. 2003. Differential psychostimulantinduced activation of neural circuits in dopamine transporter knockout and wild type mice. Neuroscience 118: 297-310.
101. Tilley, M.R. & H.H. Gu. 2008. The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J. Pharmacol. Exp. Ther. 327: 554-560.
102. Wei, H., E.R. Hill & H.H. Gu. 2009. Functional mutations inmouse norepinephrine transporter reduce sensitivity to cocaine inhibition. Neuropharmacology 56: 399-404.
103. Missale,C. et al. 1998.Dopamine receptors: fromstructure to function. Physiol. Rev. 78: 189-225.
104. Ariano, M.A. & D.R. Sibley. 1994. Dopamine receptor distribution in the rat CNS: elucidation using anti-peptide antisera directed against D1A and D3 subtypes. Brain Res. 649: 95-110.
105. Meador-Woodruff, J.H. et al. 1989. Distribution of D2 dopamine receptormRNAin rat brain. Proc.Natl.Acad. Sci. USA 86: 7625-7628.
106. Sokoloff, P. et al. 1992. Localization and function of the D3 dopamine receptor. Arzneimittelforschung 42: 224-230.
107. Defagot, M.C. et al. 1997. Distribution of D4 dopamine receptor in rat brain with sequence-specific antibodies. Brain Res. Mol. Brain Res. 45: 1-12.
108. Ciliax, B.J. et al. 2000. Dopamine D(5) receptor immunolocalization in rat and monkey brain. Synapse 37: 125-145.
109. Caine, S.B. et al. 1999. Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. J. Pharmacol. Exp. Ther. 291: 353-360.
110. Platt, D.M., J.K. Rowlett & R.D. Spealman. 2000. Dissociation of cocaine-antagonist properties andmotoric effects of the D1 receptor partial agonists SKF 83959 and SKF 77434. J. Pharmacol. Exp. Ther. 293: 1017-1026.
111. Miner, L.L. et al. 1995. Retained cocaine conditioned place preference inD1 receptor deficientmice.Neuroreport 6: 2314-2316.
112. El-Ghundi, M. et al. 1998. Disruption of dopamine D1 receptor gene expression attenuates alcohol-seeking behavior. Eur. J. Pharmacol. 353: 149-158.
113. Xu, M. et al. 2000. Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor. Brain Res. 852: 198-207.
114. Karlsson, R.M. et al. 2008. Comparison of dopamine D1andD5 receptor knockout mice for cocaine locomotor sensitization. Psychopharmacology (Berl) 200: 117-127.
115. Xu, M. et al. 1994. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 79: 945-955.
116. Karasinska, J.M. et al. 2005. Deletion of dopamine D1 and D3 receptors differentially affects spontaneous behaviour and cocaine-induced locomotor activity, reward and CREB phosphorylation. Eur. J. Neurosci. 22: 1741-1750.
117. Caine, S.B. et al. 2007. Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. J. Neurosci. 27: 13140-13150.
118. Drago, J. et al. 1996. D1 dopamine receptor-deficient mouse: cocaine-induced regulation of immediate-early gene and substance P expression in the striatum. Neuroscience 74: 813-823.
119. Caine, S.B. et al. 2002. Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. J. Neurosci. 22: 2977-2988.
120. Welter, M. et al. 2007. Absence of dopamine D2 receptors unmasks an inhibitory control over the brain circuitries activated by cocaine. Proc. Natl. Acad. Sci. USA 104: 6840-6845.
121. Chausmer,A.L. et al. 2002.Cocaine-inducedlocomotor activity and cocaine discrimination in dopamine D2 receptor mutant mice. Psychopharmacology (Berl) 163: 54-61.
122. L'Hirondel, M. et al. 1998. Lack of autoreceptormediated inhibitory control of dopamine release in striatal synaptosomes of D2 receptor-deficient mice. Brain Res. 792: 253-262.
123. Dickinson, S.D. et al. 1999. Dopamine D2 receptordeficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J. Neurochem. 72: 148-156.
124. Rouge-Pont, F. et al. 2002. Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors. J. Neurosci. 22: 3293-3301.
125. Caine, S.B. & G.F. Koob. 1993. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 260: 1814-1816.
126. Xu,M. et al. 1997. Dopamine D3 receptormutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 19: 837-848.
127. Katz, J.L. et al. 2003. Cocaine-induced locomotor activity and cocaine discrimination in dopamine D4 receptor mutant mice. Psychopharmacology (Berl) 170: 108-114.
128. Rubinstein, M. et al. 1997. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 90: 991-1001.
129. Elliot, E.E., D.R. Sibley & J.L. Katz. 2003. Locomotor and discriminative-stimulus effects of cocaine in dopamine D5 receptor knockout mice. Psychopharmacology (Berl) 169: 161-168.
130. Carta, A.R., C.R. Gerfen & H. Steiner. 2000. Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice. Neuroreport 11: 2395-2399.
131. Le Foll, B. et al. 2002. Role of the dopamineD3 receptor in reactivity to cocaine-associated cues in mice. Eur. J. Neurosci. 15: 2016-2026.
132. Doherty, J.M. et al. 2008. Contributions of dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice. Neuropsychopharmacology 33: 2648-2656.
133. Witkin, J.M. et al. 2008. The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro- 4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4 -oxazin- 9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors. J. Pharmacol. Exp. Ther. 326: 930-938.
134. Crawford, C.A. et al. 1997. Effects of repeated amphetamine treatment on the locomotor activity of the dopamine D1A-deficient mouse. Neuroreport 8: 2523-2527.
135. McDougall, S.A. et al. 2005. Importance of D(1) receptors for associative components of amphetamineinduced behavioral sensitization and conditioned activity: a study using D(1) receptor knockout mice. Psychopharmacology (Berl) 183: 20-30.
136. Karper, P.E. et al. 2002. Role of D1-like receptors in amphetamine-induced behavioral sensitization: a study using D1A receptor knockout mice. Psychopharmacology (Berl) 159: 407-414.
137. Clifford, J.J. et al. 2000. Topographical evaluation of behavioural phenotype in a line of mice with targeted gene deletion of theD2 dopamine receptor. Neuropharmacology 39: 382-390.
138. Kelly, M.A. et al. 2008. Role of dopamine D1-like receptors in methamphetamine locomotor responses of D2 receptor knockout mice. Genes Brain Behav. 7: 568-577.
139. Kruzich, P.J., K.L. Suchland & D.K. Grandy. 2004. Dopamine D4 receptor-deficient mice, congenic on the C57BL/6J background, are hypersensitive to amphetamine. Synapse 53: 131-139.
140. McNamara, R.K. et al. 2006. Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine. Synapse 60: 399-405.
141. Harrison, S.J. & J.N. Nobrega. 2009. Differential susceptibility to ethanol and amphetamine sensitization in dopamine D3 receptor-deficient mice. Psychopharmacology (Berl) 204: 49-59.
142. Ralph, R.J. et al. 1999. The dopamineD2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J. Neurosci. 19: 4627-4633.
143. Xu, R. et al. 2002. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Mol. Psychiatry 7: 1075-1082.
144. Ito, M. et al. 2008. Hyperthermic and lethal effects of methamphetamine: roles of dopamine D1 and D2 receptors. Neurosci. Lett. 438: 327-329.
145. Risbrough, V.B. et al. 2006. Differential contributions of dopamine D1, D2, and D3 receptors to MDMAinduced effects on locomotor behavior patterns in mice. Neuropsychopharmacology 31: 2349-2358.
146. Barnes, N.M. & T. Sharp. 1999. A review of central 5- HT receptors and their function. Neuropharmacology 38: 1083-1152.
147. Leysen, J.E. 2004. 5-HT2 receptors. Curr. Drug Targets CNS Neurol. Disord. 3: 11-26.
148. Kinsey, A.M. et al. 2001. Distribution of 5-ht(5A), 5- ht(5B), 5-ht(6) and 5-HT(7) receptor mRNAs in the rat brain. Brain Res. Mol. Brain Res. 88: 194-198.
149. Mengod, G. et al. 1996. 5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors. Histochem. J. 28: 747-758.
150. Muller, C.P. & J.P. Huston. 2006. Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine. Trends Pharmacol. Sci. 27: 105-112.
151. Parsons, L.H., F.Weiss & G.F. Koob. 1998. Serotonin1B receptor stimulation enhances cocaine reinforcement. J. Neurosci. 18: 10078-10089.
152. Parsons, L.H., G.F. Koob & F. Weiss. 1999. RU 24969, a 5-HT1B/1A receptor agonist, potentiates cocaineinduced increases in nucleus accumbens dopamine. Synapse 32: 132-135.
153. Castanon, N. et al. 2000. Modulation of the effects of cocaine by 5-HT1B receptors: a comparison of knockouts and antagonists. Pharmacol. Biochem. Behav. 67: 559-566.
154. Rocha, B.A. et al. 1997. Intravenous cocaine selfadministration in mice lacking 5-HT1B receptors. Pharmacol. Biochem. Behav. 57: 407-412.
155. Belzung, C. et al. 2000. Absence of cocaine-induced place conditioning in serotonin 1B receptor knock-out mice. Pharmacol. Biochem. Behav. 66: 221-225.
156. Shippenberg, T.S., R. Hen & M. He. 2000. Regionspecific enhancement of basal extracellular and cocaine-evoked dopamine levels following constitutive deletion of the Serotonin(1B) receptor. J. Neurochem. 75: 258-265.
157. Lucas, J.J., L. Segu & R. Hen. 1997. 5- Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. Mol. Pharmacol. 51: 755-763.
158. Alex, K.D. & E.A. Pehek. 2007. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 113: 296-320.
159. Rocha, B.A. et al. 2002. Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptormutant mice. J.Neurosci. 22: 10039-10045.
160. Salomon, L. et al. 2007. Paradoxical constitutive behavioral sensitization to amphetamine in mice lacking 5-HT2A receptors. Psychopharmacology (Berl) 194: 11-20.
161. Allan, A.M. et al. 2001. Conditioned place preference for cocaine is attenuated in mice over-expressing the 5-HT(3) receptor. Psychopharmacology (Berl) 158: 18-27.
162. Witkin, J.M. et al. 2007. Constitutive deletion of the serotonin-7 (5-HT(7)) receptor decreases electrical and chemical seizure thresholds. Epilepsy Res. 75: 39-45.
163. Bronsert, M.R. et al. 2001. Amphetamine-induced locomotor activation in 5-HT(1B) knockout mice: effects of injection route on acute and sensitized responses. Behav. Pharmacol. 12: 549-555.
164. Dulawa, S.C. et al. 1998. 5-HT1B receptor modulation of prepulse inhibition: recent findings in wild-type and 5-HT1B knockout mice. Ann. N. Y. Acad. Sci. 861: 79-84.
165. Dulawa, S.C. et al. 2000. Serotonin releasers increase prepulse inhibition in serotonin 1B knockout mice. Psychopharmacology (Berl) 149: 306-312.
166. Scearce-Levie, K., S.S.Viswanathan&R.Hen. 1999. Locomotor response toMDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Psychopharmacology (Berl) 141: 154-161.
167. Adell, A. & F. Artigas. 2004. The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci. Biobehav. Rev. 28: 415-431.
168. Schank, J.R. et al. 2006. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 31: 2221-2230.
169. Jasmin, L., M. Narasaiah & D. Tien. 2006. Noradrenaline is necessary for the hedonic properties of addictive drugs. Vascul. Pharmacol. 45: 243-250.
170. Drouin, C. et al. 2002. Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J. Neurosci. 22: 2873-2884.
171. Schank, J.R., L.C. Liles & D. Weinshenker. 2008. Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol. Psychiatry 63: 1007-1012.
172. Gaval-Cruz, M. et al. 2008. Effects of disulfiram and dopamine beta-hydroxylase knockout on cocaineinduced seizures. Pharmacol. Biochem. Behav. 89: 556-562.
173. Weinshenker, D. et al. 2002. Mice with chronic norepinephrine deficiency resemble amphetaminesensitized animals.Proc.Natl.Acad. Sci.USA99: 13873-13877.
174. Villegier, A.S. et al. 2003. Stimulation of postsynaptic alpha1b- and alpha2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice. Synapse 50: 277-284.
175. Sallinen, J. et al. 1998. D-amphetamine and L- 5-hydroxytryptophan- induced behaviours in mice with genetically-altered expression of the alpha2Cadrenergic receptor subtype. Neuroscience 86: 959-965.
176. Auclair, A. et al. 2004. 5-HT2A and alpha1b-adrenergic receptors entirelymediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur. J. Neurosci. 20: 3073-3084.
177. Salomon, L. et al. 2006. Behavioral sensitization to amphetamine results from an uncoupling between noradrenergic and serotonergic neurons. Proc. Natl. Acad. Sci. USA 103: 7476-7481.
178. Lahdesmaki, J. et al. 2004. Alpha2A-adrenoceptors are important modulators of the effects of D-amphetamine on startle reactivity and brain monoamines. Neuropsychopharmacology 29: 1282-1293.
179. Bexis, S. & J.R. Docherty. 2005. Role of alpha2Aadrenoceptors in the effects of MDMA on body temperature in the mouse. Br. J. Pharmacol. 146: 1-6.
180. Weinshenker, D. et al. 2008. Genetic or pharmacological blockade of noradrenaline synthesis enhances the neurochemical, behavioral, and neurotoxic effects of methamphetamine. J. Neurochem. 105: 471-483.
181. Drgon, T. et al. 2009. Genome-wide association for nicotine dependence and smoking cessation success in NIH research volunteers. Mol. Med. 15: 21-27.
182. Johnson, C. et al. 2006. Pooled association genome scanning for alcohol dependence using 104,268 SNPs: validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B: 844-853.
183. Johnson, C. et al. 2008. Genome wide association for substance dependence: convergent results from epidemiologic and research volunteer samples. BMC Med. Genet. 9: 113.
184. Liu, Q.R. et al. 2006. Addiction molecular genetics: 639,401 SNPwhole genome association identifies many "cell adhesion" genes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B: 918-925.
185. Uhl, G.R. et al. 2008. Molecular genetics of addiction and related heritable phenotypes: genome-wide association approaches identify "connectivity constellation" and drug target genes with pleiotropic effects. Ann. N. Y. Acad. Sci. 1141: 318-381.
186. Uhl, G.R. et al. 2009.Addiction genetics and pleiotropic effects of commonhaplotypes thatmake polygenic contributions to vulnerability to substance dependence. J. Neurogenet. 23: 272-282.
187. Uhl, G.R. et al. 2008. Genome-wide association for methamphetamine dependence: convergent results from 2 samples. Arch. Gen. Psychiatry 65: 345-355.
188. Uhl, G.R. et al. 2008. "Higher order" addiction molecular genetics: convergent data from genome-wide association in humans and mice. Biochem. Pharmacol. 75: 98-111.